Taspoglutide demonstrates superiority in HbA1c change versus placebo as add-on to metformin and pioglitazone….

Nurses who are interrupted while administering medication appear to have an increased risk of making medication errors, according to a report. 

Every time we send you a newsletter it is packed full of information about new drugs, therapies and ideas for improving patient care. As our staff researches these articles we are often fascinated by the discovery process and how much work goes into bringing these ideas to market. Then I …

Issak Smith University of Florida PharmD Candidate   In 2003, Congress passed the Medicare Prescription Drug, Improvement, and Modernization Act (MMA) with the hope of reducing prescription drug costs for the nation’s seniors. It was implemented on January 1st, 2006. Now several years removed, and with healthcare reform again a hot …

FDA orders recall of Baxter’s Colleague Volumetric Infusion Pumps: The FDA has notified health care professionals and consumers of a letter sent to Baxter on April 30 ordering the company to recall and destroy all Colleague Volumetric Infusion Pumps currently used in the United States — there may be as …

MicroCHIPS, Inc., Honored with 2010 Edison Best New Product Award™ The Illume™  product was awarded Gold in the Science and Medical Category, recognizing the benefit that it will bring to millions of people with diabetes who must manage their blood sugar intensively to stay healthy. The technology will be used …

International Diabetes Center at Park Nicollet has created a treatment algorithm to assist health professionals treating Type 2 diabetes. Download Glycemic Control Algorithm Chart The algorithm, based on clinical research and expert opinion, diagrams treatment options, timelines, and recommended steps. Each takes into account the patient’s targets and medication use. …

Changes in Glitazone Use 2003-2009: From 2003 through 2005, glitazone use increased steadily. From February 2005 to January 2007, rosiglitazone use decreased by 16% annually while pioglitazone use increased at an annual rate of 14%. During a period of FDA advisories, rosiglitazone use declined sharply from 0.42 million monthly treatment …

Mortality Rates Differ with Different Sulfonylureas: The risk for overall mortality is similar in patients with Type 2 diabetes receiving glipizide, glyburide, or glimepiride monotherapy, according to the results of a retrospective cohort study. The findings suggest that glimepiride may be the preferred sulfonylurea in patients with underlying coronary artery …

Reanalysis of an ACCORD study refutes link between intensive therapy, higher death risk….